Format

Send to

Choose Destination
J Med Chem. 2017 Mar 9;60(5):2052-2070. doi: 10.1021/acs.jmedchem.6b01840. Epub 2017 Feb 28.

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

Author information

1
QIMR Berghofer Medical Research Institute , 300 Herston Road, Herston, Queensland 4006, Australia.
2
Oncogenic Signaling Laboratory, Centre for Cancer Research, Hudson Institute of Medical Research , 27 Wright Street, Clayton, Victoria 3168, Australia.

Abstract

The DYRK family contains kinases that are up-regulated in malignancy and control several cancer hallmarks. To assess the anticancer potential of inhibitors targeting DYRK kinases, we developed a series of novel DYRK inhibitors based on the 7-azaindole scaffold. All compounds were tested for their ability to inhibit DYRK1A, DYRK1B, DYRK2, and the structurally related CLK1. The library was screened for anticancer efficacy in established and stem cell-like glioblastoma cell lines. The most potent inhibitors (IC50 ≤ 50 nM) significantly decreased viability, clonogenic survival, migration, and invasion of glioblastoma cells. Target engagement was confirmed with genetic knockdown and the cellular thermal shift assay. We demonstrate that DYRK1A's thermal stability in cells is increased upon compound treatment, confirming binding in cells. In summary, we present synthesis, structure-activity relationship, and efficacy in glioblastoma-relevant models for a library of novel 7-azaindoles.

PMID:
28206758
DOI:
10.1021/acs.jmedchem.6b01840
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center